Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes

50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial

“…[35][36][37][38][39][40] Series using heterogeneous dose distribution to 50 Gy using CyberKnife have reported grade 1 to 2 acute GU toxicities of 50% to 60%. 41,42 A recent study using high-dose-rate brachytherapy to deliver a boost (18.75 Gy in 1 fraction) to the DIN after SBRT (37.5 Gy in 15 fractions) reported 20% acute grade 2 GU toxicity that persisted in 6.7% of the patients. 43 In a multicenter dose-escalation phase 1-2 SBRT study in patients treated to 50 Gy in 5 fractions, Boike et al 13 reported a grade 1 to 2 acute GU toxicity of 60%.…”

Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies

“…W.C.J and D.E.S independently extracted data from the 38 identified studies. [37][38][39][40][41][42][43][44][45][46][47][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68] Variables extracted included study and patient-level characteristics, such as study type, phase of trial, sample size, dose per fraction, fraction number, duration of follow-up, age, clinical tumor stage, baseline prostate-specific antigen, National Comprehensive Cancer Network (NCCN) 69 risk group of enrolled patients, receipt of androgen-deprivation therapy (ADT), bRFS, physician-reported toxicity, and patientreported QOL, if reported. Individual patient data was not used.…”

Changes in prostate orientation due to removal of a Foley catheter

“…[1][2][3][4][5] With these ultra-hypofractionated schedules, there has been concern regarding the potential for increased toxicity, and extra measures are being investigated to minimize these potential side effects. 1,6,7 Prostate SBRT has been referred to by some as virtual high dose-rate (HDR) brachytherapy, due to the analogous high dose per fraction. 8 Brachytherapy has been associated with the potential for increased genitourinary toxicity and risk for urethral structures compared to fractionated external beam radiotherapy, and similar concerns exist with prostate SBRT.…”